DNA fusion gene vaccines against cancer: from the laboratory to the clinic

Immunological Reviews
Freda K StevensonDelin Zhu

Abstract

Vaccination against target antigens expressed by cancer cells has now become a realistic goal. DNA vaccines provide a direct link between identification of genetic markers in tumors and vaccine formulation. Simplicity of manufacture facilitates construction of vaccines against disease subsets or even for individual patients. To engage an immune system that exists to fight pathogens, we have developed fusion gene vaccines encoding tumor antigens fused to pathogen-derived sequences. This strategy activates high levels of T-cell help, the key to induction and maintenance of effective immunity. We have dissected the immunogenic tetanus toxin to obtain specific sequences able to activate antibody, CD4+, or CD8+ T cells to attack selected fused tumor antigens. Principles established in preclinical models are now being tested in patients. So far, objective immune responses against idiotypic antigen of neoplastic B cells have been observed in patients with B-cell malignancies and in normal transplant donors. These responses provide a platform for testing physical methods to improve DNA delivery and strategies to boost responses. For cancer, demands are high, because vaccines have to activate powerful immunity against weak antigens, oft...Continue Reading

References

Jul 27, 1990·Science·H M EtlingerA Trzeciak
Oct 1, 1991·Infection and Immunity·C C PeetersG T Rijkers
Jan 1, 1989·International Reviews of Immunology·A J George, F K Stevenson
Jan 1, 1972·Advances in Immunology·D H Katz, B Benacerraf
Jun 26, 1980·Nature·L A HerzenbergL A Herzenberg
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·S T JuA Marshak-Rothstein
Jun 1, 1995·Immunological Reviews·F K StevensonR E Hawkins
Jan 1, 1994·Pharmacology & Therapeutics·B Wiemann, C O Starnes
Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·T C WuD M Pardoll
Sep 1, 1996·Nature Medicine·A D SyrengelasR Levy
Oct 4, 1996·Science·J D AltmanM M Davis
Jan 1, 1996·Advances in Cancer Research·S A RosenbergR Wang
Apr 5, 1997·Annals of the New York Academy of Sciences·C C Goodnow
Jul 7, 1997·The Journal of Experimental Medicine·S R BennettW R Heath
Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·J van BergenF Koning
Jun 1, 1997·Immunological Reviews·H E Heslop, C M Rooney
Jan 1, 1997·International Journal of Clinical & Laboratory Research·B J Van den Eynde, T Boon
Oct 23, 1997·Nature Structural Biology·T C UmlandM Sax
Dec 16, 1997·Proceedings of the National Academy of Sciences of the United States of America·K SuzueR A Young
Mar 24, 1998·Annual Review of Medicine·F Dazzi, J M Goldman
Jun 12, 1998·Nature·A Lanzavecchia
Jul 29, 1998·International Journal of Cancer. Journal International Du Cancer·P ChauxP van der Bruggen
Dec 24, 1998·The New England Journal of Medicine·T E Starzl, R M Zinkernagel
Jun 8, 1999·Annual Review of Immunology·J W Yewdell, J R Bennink

❮ Previous
Next ❯

Citations

Sep 5, 2009·Cancer Immunology, Immunotherapy : CII·Olga Radkevich-BrownWei-Zen Wei
Aug 29, 2012·Cancer Immunology, Immunotherapy : CII·Joel F AldrichRobert K Bright
Jul 19, 2012·World Journal of Microbiology & Biotechnology·Hongwei HouJinyan Hou
Feb 28, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Manuel E EngelhornJedd D Wolchok
Jan 26, 2008·Nature Reviews. Cancer·Jason RiceFreda K Stevenson
Mar 22, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Barbara-ann GuinnAlbert B Deisseroth
Jan 5, 2006·The Journal of Experimental Medicine·Concetta BeninatiGiuseppe Teti
Aug 12, 2005·Current Opinion in Oncology·Sara A Hurvitz, John M Timmerman
Aug 5, 2004·Proceedings of the National Academy of Sciences of the United States of America·Freda K StevensonJason Rice
Apr 15, 2010·Cancer Immunology, Immunotherapy : CII·Emanuela SignoriVito Michele Fazio
Mar 20, 2014·The Journal of Clinical Investigation·John G FacciponteAndrea Facciabene
Oct 6, 2007·Expert Opinion on Biological Therapy·Pieranna ChiarellaVito Michele Fazio
Apr 7, 2010·Journal of Biomedicine & Biotechnology·Daniela FiorettiMonica Rinaldi
Aug 28, 2007·Critical Reviews in Oncology/hematology·S MittalM A Vickers
Jan 6, 2011·International Journal of Cancer. Journal International Du Cancer·Koen OosterhuisJohn B Haanen
Dec 24, 2005·Pathology·Kristen J RadfordDerek N J Hart
Aug 13, 2015·Cancer Immunology, Immunotherapy : CII·Stefano UgelAndrea Facciabene
Jul 25, 2006·Advances in Cancer Research·Aniruddha ChoudhuryHåkan Mellstedt
Apr 24, 2014·Therapeutic Advances in Vaccines·Emeline Ragonnaud, Peter Holst
Jun 22, 2005·Bone Marrow Transplantation·S S NeelapuL W Kwak
Sep 11, 2008·Nature Reviews. Genetics·Michele A Kutzler, David B Weiner
May 10, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sarah BuchanJason Rice
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joanna N RadcliffeStephen M Thirdborough
Feb 1, 2006·Personalized Medicine·Mike WhelanAngus Dalgleish
Dec 7, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joanna N RadcliffeStephen M Thirdborough

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.